Peptides DB

Research-centric peptide and protocol reference hub

Argireline vs GHK-Cu

Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team

Argireline: Research use — not FDA-approvedGHK-Cu: Research use — not FDA-approved

A data-driven comparison of Argireline and GHK-Cu (also searched as GHK-Cu vs Argireline) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.

Verdict

Argireline centers on skin, while GHK-Cu leans toward skin. On indexed research, GHK-Cu is ahead (Argireline: 4 studies, Preclinical; GHK-Cu: 5, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.

Key takeaways

  • Argireline is strongest for skin; GHK-Cu for skin.
  • Evidence: Argireline Preclinical (4 studies) vs GHK-Cu Preclinical (5).
  • Both are research-use compounds — not FDA-approved.

Effect profiles, overlaid

HealingMuscleMetabolicNeuroSleepInflammationSkin
ArgirelineGHK-Cu

At a glance

ArgirelinePreclinical
Strongest: SkinStudies: 4Level:
GHK-CuPreclinical

Copper Peptide | Skin Regeneration & Anti-Aging Compound

Strongest: SkinStudies: 5Level: Well Studied

Argireline vs GHK-Cu: side-by-side

MetricArgirelineGHK-Cu
ClassSkin
Regulatory statusResearch use onlyResearch use only
Evidence gradePreclinicalPreclinical
Studies indexed45
Research levelWell Studied
Strongest effectSkin & aestheticsSkin & aesthetics
Healing & recovery0.04.0
Muscle & body comp0.01.0
Metabolic & appetite0.03.0
Neuro & mood1.02.0
Sleep & circadian0.00.0
Inflammation & immune2.04.0
Skin & aesthetics4.05.0

▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).

Mechanism & pharmacokinetics

PropertyArgirelineGHK-Cu
MechanismCopper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signaling
RouteTopical / subcutaneous

Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.

What is Argireline?

### Summary Argireline, also known as Acetyl Hexapeptide-3, is a synthetic peptide commonly utilized in cosmetic formulations for its potential anti-aging properties. It is often marketed as a topical alternative to botulinum toxin, aiming to reduce the appearance of fine lines and wrinkles.

Full Argireline profile, mechanism & studies →

What is GHK-Cu?

Copper-binding tripeptide widely used in skin, hair, and wound-healing contexts, with systemic effects explored in research.

Full GHK-Cu profile, mechanism & studies →

Which is better for your goal?

GoalBetter fitWhy
HealingGHK-Cu4.0/5 effect signal
MuscleGHK-Cu1.0/5 effect signal
MetabolicGHK-Cu3.0/5 effect signal
NeuroGHK-Cu2.0/5 effect signal
InflammationGHK-Cu4.0/5 effect signal
SkinGHK-Cu5.0/5 effect signal

Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.

Can you stack Argireline and GHK-Cu?

People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.

Argireline vs GHK-Cu: side effects

Argireline

No community-reported effects logged yet.

GHK-Cu
  • improved skin texture18
  • localized irritation5
  • transient tingling4
  • gi upset1
  • headache1

Anonymous community reports (count = number of reports), not clinical incidence rates.

What the research says

Argireline has 4 approved studies indexed (Preclinical), and GHK-Cu has 5 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.

Frequently asked questions

Is Argireline or GHK-Cu better?

It depends on your goal. Argireline is strongest for skin; GHK-Cu for skin. GHK-Cu has more indexed studies (5). See the goal-by-goal breakdown above.

Is Argireline or GHK-Cu better for weight loss?

GHK-Cu shows the stronger metabolic & appetite profile (3.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.

Is Argireline or GHK-Cu better for muscle?

GHK-Cu leads on the muscle & body-composition axis (1.0/5).

Which has more research, Argireline or GHK-Cu?

Argireline has 4 approved studies indexed (Preclinical); GHK-Cu has 5 (Preclinical). Higher counts mean more to read, not proven superiority.

Can you stack Argireline and GHK-Cu?

Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.

What are the side effects of Argireline vs GHK-Cu?

Argireline: no community-reported effects logged yet. GHK-Cu: improved skin texture, localized irritation, transient tingling. These are anonymous reports, not incidence rates — see each profile.

Is Argireline or GHK-Cu FDA-approved?

Argireline is a research-use compound and is not FDA-approved. GHK-Cu is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.

Is GHK-Cu better than Argireline?

For skin, GHK-Cu has the edge; for skin, Argireline does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.

Comparing related peptides

Regulatory & legal status

Argireline and GHK-Cu are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.